What's Happening?
Brii Biosciences presented late-breaking data from its Phase 2 ENSURE study at the AASLD 2025, showcasing the potential of BRII-179 as a curative treatment for chronic hepatitis B. The study demonstrated
durable hepatitis B surface antigen (HBsAg) loss in BRII-179 anti-HBs responders treated with elebsiran and pegylated interferon alfa. The data suggests the possibility of shortening treatment duration for responders, with 42% maintaining HBsAg loss at 24 weeks post-treatment. Brii Bio is conducting additional Phase 2b trials to further define BRII-179's role in HBV treatment.
Why It's Important?
The promising results from the ENSURE study highlight BRII-179's potential to offer a functional cure for chronic hepatitis B, a significant global health challenge affecting millions. The ability to shorten treatment duration could improve patient compliance and outcomes, making the therapy more accessible. Brii Bio's efforts to advance HBV treatment reflect the growing focus on innovative solutions for infectious diseases, with implications for public health and healthcare systems worldwide.
What's Next?
Brii Bio is conducting two additional Phase 2b trials, ENRICH and ENHANCE, to optimize combination regimens for pivotal studies. These trials aim to evaluate BRII-179's role in priming HBV-specific immunity and its effectiveness in combination with other therapies. The company plans to present end-of-treatment data in 2026, which will be crucial for determining the next steps in BRII-179's development and potential regulatory approval.
Beyond the Headlines
The development of BRII-179 underscores the importance of addressing infectious diseases with high unmet medical needs. The focus on HBV treatment highlights ethical considerations in ensuring equitable access to innovative therapies, particularly in regions with high infection rates. Brii Bio's work reflects broader trends in biotechnology, where collaboration and strategic partnerships are key to advancing public health solutions.
